JP2018528257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528257A5 JP2018528257A5 JP2018521190A JP2018521190A JP2018528257A5 JP 2018528257 A5 JP2018528257 A5 JP 2018528257A5 JP 2018521190 A JP2018521190 A JP 2018521190A JP 2018521190 A JP2018521190 A JP 2018521190A JP 2018528257 A5 JP2018528257 A5 JP 2018528257A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- group
- amino acid
- terminus
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims description 110
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 244000137850 Marrubium vulgare Species 0.000 claims description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Chemical group OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- -1 polyethylene Polymers 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Chemical group Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Chemical group OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Chemical group CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000011729 δ-tocotrienol Chemical group 0.000 claims description 3
- 235000019144 δ-tocotrienol Nutrition 0.000 claims description 3
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical group OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 claims description 3
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Chemical group OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- 229940064063 alpha tocotrienol Drugs 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Chemical group Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 claims description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 2
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Chemical group OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 claims description 2
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Chemical group Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical group OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims description 2
- 239000011730 α-tocotrienol Chemical group 0.000 claims description 2
- 235000019145 α-tocotrienol Nutrition 0.000 claims description 2
- 239000011723 β-tocotrienol Chemical group 0.000 claims description 2
- 235000019151 β-tocotrienol Nutrition 0.000 claims description 2
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical group OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 claims description 2
- 239000011722 γ-tocotrienol Chemical group 0.000 claims description 2
- 235000019150 γ-tocotrienol Nutrition 0.000 claims description 2
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical group OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- JWXLCQHWBFHMOI-NIQMUPOESA-N bis[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] carbonate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C(C1)[C@]2(C)CC[C@@H]1OC(=O)O[C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 JWXLCQHWBFHMOI-NIQMUPOESA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 239000002872 contrast media Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000011572 manganese Substances 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- OBPOCAKICKFMGM-PGUFJCEWSA-N 2-[di(hexadecanoyl)amino]ethyl [(2R)-2,3-dihydroxypropyl] hydrogen phosphate Chemical group C(CCCCCCCCCCCCCCC)(=O)N(CCOP(OC[C@@H](CO)O)(=O)O)C(CCCCCCCCCCCCCCC)=O OBPOCAKICKFMGM-PGUFJCEWSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- LRCTTYSATZVTRI-UHFFFAOYSA-L cyclohexane-1,2-diamine;platinum(4+);tetradecanoate Chemical compound [Pt+4].NC1CCCCC1N.CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O LRCTTYSATZVTRI-UHFFFAOYSA-L 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229950004962 miriplatin Drugs 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021137990A JP7378446B2 (ja) | 2015-07-10 | 2021-08-26 | 疎水性薬剤の効能を改善するための配合物 |
| JP2023123206A JP2023153906A (ja) | 2015-07-10 | 2023-07-28 | 疎水性薬剤の効能を改善するための配合物 |
| JP2025144586A JP2025172117A (ja) | 2015-07-10 | 2025-09-01 | 疎水性薬剤の効能を改善するための配合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562190909P | 2015-07-10 | 2015-07-10 | |
| US62/190,909 | 2015-07-10 | ||
| PCT/US2016/041544 WO2017011312A1 (en) | 2015-07-10 | 2016-07-08 | Formulations for improving the efficacy of hydrophobic drugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021137990A Division JP7378446B2 (ja) | 2015-07-10 | 2021-08-26 | 疎水性薬剤の効能を改善するための配合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018528257A JP2018528257A (ja) | 2018-09-27 |
| JP2018528257A5 true JP2018528257A5 (enExample) | 2019-08-15 |
Family
ID=57758158
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521190A Pending JP2018528257A (ja) | 2015-07-10 | 2016-07-08 | 疎水性薬剤の効能を改善するための配合物 |
| JP2021137990A Active JP7378446B2 (ja) | 2015-07-10 | 2021-08-26 | 疎水性薬剤の効能を改善するための配合物 |
| JP2023123206A Pending JP2023153906A (ja) | 2015-07-10 | 2023-07-28 | 疎水性薬剤の効能を改善するための配合物 |
| JP2025144586A Pending JP2025172117A (ja) | 2015-07-10 | 2025-09-01 | 疎水性薬剤の効能を改善するための配合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021137990A Active JP7378446B2 (ja) | 2015-07-10 | 2021-08-26 | 疎水性薬剤の効能を改善するための配合物 |
| JP2023123206A Pending JP2023153906A (ja) | 2015-07-10 | 2023-07-28 | 疎水性薬剤の効能を改善するための配合物 |
| JP2025144586A Pending JP2025172117A (ja) | 2015-07-10 | 2025-09-01 | 疎水性薬剤の効能を改善するための配合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10532105B2 (enExample) |
| EP (1) | EP3319980B8 (enExample) |
| JP (4) | JP2018528257A (enExample) |
| KR (1) | KR20180027532A (enExample) |
| CN (1) | CN108350036B (enExample) |
| AU (1) | AU2016291597B2 (enExample) |
| CA (1) | CA2991655A1 (enExample) |
| DK (1) | DK3319980T3 (enExample) |
| EA (1) | EA201890271A1 (enExample) |
| IL (1) | IL256486B2 (enExample) |
| MX (1) | MX384254B (enExample) |
| WO (1) | WO2017011312A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3319980T3 (da) * | 2015-07-10 | 2021-11-22 | Peptinovo Biopharma Inc | Formuleringer til forbedring af virkningen af hydrofobe lægemidler |
| US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
| CN114401736A (zh) * | 2019-08-13 | 2022-04-26 | 佩蒂诺沃生物制药公司 | 用于治疗伴随癌症治疗发生的化学疗法诱导的周围神经病变的palm |
| WO2022035818A2 (en) * | 2020-08-11 | 2022-02-17 | Peptinovo Biopharma, Inc. | Peptides and formulations for cancer treatment |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US20040234588A1 (en) | 2000-09-21 | 2004-11-25 | University Of Georgia Research Foundation, Inc. | Artificial lipoprotein carrier system for bioactive materials |
| AUPR798901A0 (en) | 2001-09-28 | 2001-10-25 | Medvet Science Pty. Ltd. | Spheroidal hdl particles with a defined phospholipid composition |
| BR0310099A (pt) | 2002-05-17 | 2007-03-20 | Esperion Therapeutics Inc | método para tratar dislipidemia ou uma doença associada com a dislipidemia |
| KR101186210B1 (ko) | 2002-12-03 | 2012-10-08 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체 |
| US8097283B2 (en) | 2004-01-15 | 2012-01-17 | Mount Sinai School Of Medicine | Methods and compositions for imaging |
| GB0525214D0 (en) | 2005-12-12 | 2006-01-18 | Bioinvent Int Ab | Biological materials and uses thereof |
| US20080249123A1 (en) * | 2007-04-05 | 2008-10-09 | Wyeth | Wortmannin-rapamycin conjugate and uses thereof |
| US20090110739A1 (en) | 2007-05-15 | 2009-04-30 | University Of North Texas Health Science Center At Forth Worth | Targeted cancer chemotherapy using synthetic nanoparticles |
| BRPI0818881A2 (pt) | 2007-10-23 | 2015-05-05 | Cleveland Clinic Foundation | Polipetídeo purificado, composição farmacêutica e métodos de de tratar distúrbios cardiovasculares, de promover efluxo de colesterol a partir de uma célula, de melhorar um ou mais sintomas de uma condição inflamatória em um indivíduo, de mitigar perda de oxidante mpo de função de efluxo de colesterol e de tratar dano de célula endotelial em um indivíduo |
| WO2009059450A1 (en) * | 2007-11-05 | 2009-05-14 | Shanghai Jiaotong University | Peptide ligand directed drug delivery |
| US20110020242A1 (en) | 2007-12-12 | 2011-01-27 | Gang Zheng | High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
| US8058069B2 (en) * | 2008-04-15 | 2011-11-15 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
| RU2011101536A (ru) * | 2008-06-18 | 2012-07-27 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us) | Усовершенствованные пептидные медиаторы оттока холестерина |
| CN102215844A (zh) * | 2008-09-17 | 2011-10-12 | 恩多塞特公司 | 抗叶酸剂的叶酸受体结合轭合物 |
| EP2393472B1 (en) | 2008-12-05 | 2019-06-05 | NanoMed Holdings Pty Ltd | Amphiphile prodrugs |
| EP2658993B1 (en) * | 2010-12-31 | 2014-10-01 | Alphacore Pharma LLC | Detection of lcat activity |
| JP2014132832A (ja) * | 2011-05-10 | 2014-07-24 | Sekisui Chem Co Ltd | 医薬、機能性食品、目的蛋白質の安定化方法、融合蛋白質、核酸、並びに、組換え体 |
| WO2013188763A1 (en) * | 2012-06-15 | 2013-12-19 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
| CN103393597B (zh) * | 2013-07-02 | 2015-06-17 | 北京大学 | 疏水性肽修饰的注射用长循环脂质体给药系统 |
| CN104558117B (zh) * | 2013-10-25 | 2018-01-16 | 复旦大学 | 一种乙酰胆碱受体介导靶向的d构型多肽及其应用 |
| US10220046B2 (en) | 2014-07-14 | 2019-03-05 | The Regents Of The University Of Michigan | Compositions and methods for disease treatment using nanoparticle delivered compounds |
| WO2016019333A1 (en) | 2014-07-31 | 2016-02-04 | Kinemed, Inc. | The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
| DK3319980T3 (da) * | 2015-07-10 | 2021-11-22 | Peptinovo Biopharma Inc | Formuleringer til forbedring af virkningen af hydrofobe lægemidler |
-
2016
- 2016-07-08 DK DK16824940.7T patent/DK3319980T3/da active
- 2016-07-08 CA CA2991655A patent/CA2991655A1/en active Pending
- 2016-07-08 AU AU2016291597A patent/AU2016291597B2/en active Active
- 2016-07-08 MX MX2018000140A patent/MX384254B/es unknown
- 2016-07-08 EP EP16824940.7A patent/EP3319980B8/en active Active
- 2016-07-08 CN CN201680040636.6A patent/CN108350036B/zh active Active
- 2016-07-08 US US15/743,098 patent/US10532105B2/en active Active
- 2016-07-08 JP JP2018521190A patent/JP2018528257A/ja active Pending
- 2016-07-08 KR KR1020187003118A patent/KR20180027532A/ko not_active Ceased
- 2016-07-08 WO PCT/US2016/041544 patent/WO2017011312A1/en not_active Ceased
- 2016-07-08 EA EA201890271A patent/EA201890271A1/ru unknown
-
2017
- 2017-12-21 IL IL256486A patent/IL256486B2/en unknown
-
2021
- 2021-08-26 JP JP2021137990A patent/JP7378446B2/ja active Active
-
2023
- 2023-07-28 JP JP2023123206A patent/JP2023153906A/ja active Pending
-
2025
- 2025-09-01 JP JP2025144586A patent/JP2025172117A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107337728B (zh) | 脂蛋白复合物及其制备和用途 | |
| ES2342258T3 (es) | Peptidos administrados oralmente para mejorar la aterosclerosis. | |
| JP2012518006A5 (enExample) | ||
| JP2018528257A5 (enExample) | ||
| EP2574623A3 (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
| JP2011507807A5 (enExample) | ||
| US20230302145A1 (en) | Surfactant protein c mimics displaying pathogen- or allergen-binding moieties | |
| US11434267B2 (en) | Peptides having reduced toxicity that stimulate cholesterol efflux | |
| KR101993937B1 (ko) | 염증 억제용 펩티드 | |
| JP2011525181A (ja) | コレステロール流出の改良型ペプチドメディエータ | |
| US7153490B2 (en) | Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumors | |
| JP6810690B2 (ja) | 疾患組織に対する選択性を有するファルマコフォアを含む組成物およびその生成方法 | |
| US20050058697A1 (en) | Cell penetrating therapeutic agents | |
| CN110612097B (zh) | 脂质体药物递送媒介物 | |
| WO2002066067A2 (en) | Albumin-based drug delivery system and antimicrobial peptides | |
| KR20180027532A (ko) | 소수성 약물의 효능 개선용 제형 | |
| CA3127985A1 (en) | Bi-specific extracellular matrix binding peptides and methods of use thereof | |
| CN111164094B (zh) | 抗癌肽及其用途 | |
| Chiangjong et al. | Membrane Attacking Peptides: A New Involving Cancer Therapy | |
| Dathe et al. | 28 Cellular Uptake of Liposomal and Micellar Carriers Mediated by ApoE-Derived Peptides | |
| JPWO2021030359A5 (enExample) | ||
| WO2012014046A2 (en) | Supramolecular aggregates as drug carriers on cell expressing receptors for branched neurotensin |